Cargando…
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids
Glatiramer Acetate (GA) has provided safe and effective treatment for multiple sclerosis (MS) patients for two decades. It acts as an antigen, yet the precise mechanism of action remains to be fully elucidated, and no validated pharmacokinetic or pharmacodynamic biomarkers exist. In order to better...
Autores principales: | Kolitz, Sarah, Hasson, Tal, Towfic, Fadi, Funt, Jason M., Bakshi, Shlomo, Fowler, Kevin D., Laifenfeld, Daphna, Grinspan, Augusto, Artyomov, Maxim N., Birnberg, Tal, Schwartz, Rivka, Komlosh, Arthur, Hayardeny, Liat, Ladkani, David, Hayden, Michael R., Zeskind, Benjamin, Grossman, Iris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441120/ https://www.ncbi.nlm.nih.gov/pubmed/25998228 http://dx.doi.org/10.1038/srep10191 |
Ejemplares similares
-
Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
por: Towfic, Fadi, et al.
Publicado: (2014) -
Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets
por: Fowler, Kevin D., et al.
Publicado: (2015) -
Response to the Letter-to-the Editor by Cohen et al. concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19–30.https://doi.org/10.1016/j.ensci.2018.05.006
por: Melamed-Gal, Sigal, et al.
Publicado: (2018) -
Pridopidine activates neuroprotective pathways impaired in Huntington Disease
por: Geva, Michal, et al.
Publicado: (2016) -
A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
por: Ross, Colin J., et al.
Publicado: (2017)